BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22394059)

  • 1. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
    Hagel C; Stemmer-Rachamimov AO; Bornemann A; Schuhmann M; Nagel C; Huson S; Evans DG; Plotkin S; Matthies C; Kluwe L; Mautner VF
    Neuropathology; 2012 Dec; 32(6):611-6. PubMed ID: 22394059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral and spinal cord tanycytic ependymomas in a young adult with a mutation in the NF2 gene.
    Kuga Y; Ohnishi H; Kodama Y; Takakura S; Hayashi M; Yagi R; Fukutome K; Matsushima K; Okamoto K; Taomoto K; Takahashi H
    Neuropathology; 2014 Aug; 34(4):406-13. PubMed ID: 24612193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
    Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
    Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome.
    Pitchford CW; Schwartz HS; Atkinson JB; Cates JM
    Am J Surg Pathol; 2006 Dec; 30(12):1624-9. PubMed ID: 17122521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
    J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of lower cranial nerve schwannoma with spinal ependymoma in ? NF2.
    Kumar R; Sharma KH; Chhabra DK
    Neurol India; 1999 Jun; 47(2):145-7. PubMed ID: 10447465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas.
    Singh PK; Gutmann DH; Fuller CE; Newsham IF; Perry A
    Mod Pathol; 2002 May; 15(5):526-31. PubMed ID: 12011257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?
    Seppälä MT; Sainio MA; Haltia MJ; Kinnunen JJ; Setälä KH; Jääskeläinen JE
    J Neurosurg; 1998 Jul; 89(1):36-41. PubMed ID: 9647170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas.
    von Haken MS; White EC; Daneshvar-Shyesther L; Sih S; Choi E; Kalra R; Cogen PH
    Genes Chromosomes Cancer; 1996 Sep; 17(1):37-44. PubMed ID: 8889505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.
    Ebert C; von Haken M; Meyer-Puttlitz B; Wiestler OD; Reifenberger G; Pietsch T; von Deimling A
    Am J Pathol; 1999 Aug; 155(2):627-32. PubMed ID: 10433955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.
    Plotkin SR; O'Donnell CC; Curry WT; Bove CM; MacCollin M; Nunes FP
    J Neurosurg Spine; 2011 Apr; 14(4):543-7. PubMed ID: 21294614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas.
    Rubio MP; Correa KM; Ramesh V; MacCollin MM; Jacoby LB; von Deimling A; Gusella JF; Louis DN
    Cancer Res; 1994 Jan; 54(1):45-7. PubMed ID: 8261460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
    Ruggieri M; Iannetti P; Polizzi A; La Mantia I; Spalice A; Giliberto O; Platania N; Gabriele AL; Albanese V; Pavone L
    Neuropediatrics; 2005 Feb; 36(1):21-34. PubMed ID: 15776319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurofibromatosis type 2].
    Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
    Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety.
    Mautner VF; Tatagiba M; Lindenau M; Fünsterer C; Pulst SM; Baser ME; Kluwe L; Zanella FE
    AJR Am J Roentgenol; 1995 Oct; 165(4):951-5. PubMed ID: 7676998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases.
    Ferrer M; Schulze A; Gonzalez S; Ferreiro V; Ciavarelli P; Otero J; Giliberto F; Basso A; Szijan I
    Neurosci Lett; 2010 Aug; 480(1):49-54. PubMed ID: 20553997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanycytic ependymoma in association with neurofibromatosis type 2.
    Kobata H; Kuroiwa T; Isono N; Nagasawa S; Ohta T; Tsutsumi A
    Clin Neuropathol; 2001; 20(3):93-100. PubMed ID: 11430494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of spinal tumors in neurofibromatosis type 2 patients.
    Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
    Neurol Neurochir Pol; 2016; 50(1):31-5. PubMed ID: 26851687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis type 2.
    Evans DG
    Handb Clin Neurol; 2015; 132():87-96. PubMed ID: 26564072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.